What is OKYO Pharma Limited?
OKYO Pharma Limited, a clinical-stage ophthalmology company, develops therapies for corneal and anterior diseases in the United Kingdom.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
OKYO Pharma Limited, a clinical-stage ophthalmology company, develops therapies for corneal and anterior diseases in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase 2 clinical trials for the treatment of dry eye disease and neuropathic corneal pain. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 70.85M.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.